NCT05267392 - Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

July 31, 2023

Study Completion Date

January 31, 2024

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

Durvalumab

Patients will receive 1500 mg of durvalumab (MEDI4736) via IV infusion

OTHER

standard of care RT/RCT

Trial Locations (1)

RECRUITING

Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto